| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $307,244 | 2 | 67 |
Sells | $314 | 1 | 33 |
| Schwartz Aharon | director | 1 | $205,884 | 0 | $0 | $205,884 |
| Bashan Dror | PRESIDENT AND CEO | 1 | $101,360 | 0 | $0 | $101,360 |
| Bar-Shalev Amos | director | 0 | $0 | 1 | $314 | $-314 |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Over the last 12 months, insiders at Protalix BioTherapeutics, Inc. have bought $307,244 and sold $314 worth of Protalix BioTherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Protalix BioTherapeutics, Inc. have bought $163,886 and sold $1.04M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Schwartz Aharon (director) — $205,884. Bashan Dror (PRESIDENT AND CEO) — $101,360.
The last purchase of 56,000 shares for transaction amount of $101,360 was made by Bashan Dror (PRESIDENT AND CEO) on 2025‑12‑19.
| 2025-12-19 | Bashan Dror | PRESIDENT AND CEO | 56,000 0.0729% | $1.81 | $101,360 | +28.90% | ||
| 2025-11-18 | Sale | Bar-Shalev Amos | director | 168 0.0002% | $1.87 | $314 | +12.23% | |
| 2025-06-10 | Schwartz Aharon | director | 129,000 0.1637% | $1.60 | $205,884 | +22.78% | ||
| 2023-10-19 | Bashan Dror | PRESIDENT AND CEO | 64,516 0.0878% | $1.40 | $90,484 | -17.12% | ||
| 2023-01-03 | Schwartz Aharon | director | 110,000 0.1979% | $1.42 | $155,815 | +30.66% | ||
| 2022-04-11 | Bashan Dror | President and CEO | 68,000 0.1528% | $1.50 | $102,000 | -19.15% | ||
| 2021-06-03 | Sale | Dexcel Pharma Technologies Ltd. | 10 percent owner | 857,506 1.9156% | $2.25 | $1.93M | -48.20% | |
| 2021-06-02 | Sale | Dexcel Pharma Technologies Ltd. | 10 percent owner | 61,211 0.1389% | $2.56 | $156,553 | -53.63% | |
| 2020-04-07 | Schwartz Aharon | director | 64,000 0.1994% | $2.43 | $155,264 | +53.33% | ||
| 2017-05-16 | Manor Moshe | President & CEO | 50,000 0.0383% | $0.81 | $40,500 | -20.48% | ||
| 2016-12-02 | Sale | Camber Capital Management LLC | 10 percent owner | 2.5M 2.5199% | $0.32 | $792,000 | +144.13% | |
| 2015-12-14 | Maimon Yossi | Vice President & CFO | 10,000 0.01% | $0.78 | $7,800 | -2.56% | ||
| 2015-10-19 | Camber Capital Management LLC | 10 percent owner | 4M 4.0937% | $1.00 | $4M | -18.37% | ||
| 2014-08-13 | Sale | Bronfeld Zeev | 4.4M 4.4447% | $2.47 | $10.87M | -21.67% | ||
| 2014-08-13 | Sale | Bio-Cell Ltd | 10 percent owner | 4.4M 4.4447% | $2.47 | $10.87M | -21.67% | |
| 2013-08-15 | Sale | Akirov Alfred | director | 2,330 0.0025% | $5.07 | $11,813 | -14.98% | |
| 2013-08-14 | Sale | Akirov Alfred | director | 110,000 0.1193% | $5.05 | $555,750 | -14.78% | |
| 2013-03-12 | Sale | Akirov Alfred | director | 10,000 0.0108% | $5.70 | $57,000 | -12.63% | |
| 2013-03-11 | Sale | Akirov Alfred | director | 18,300 0.0198% | $5.72 | $104,737 | -12.63% | |
| 2013-03-08 | Sale | Akirov Alfred | director | 16,898 0.0182% | $5.86 | $99,068 | -14.94% |
| Schwartz Aharon | director | 303000 0.3761% | $702,960.00 | 3 | 0 | +42% |
| Bashan Dror | PRESIDENT AND CEO | 188516 0.234% | $437,357.12 | 3 | 0 | <0.0001% |
| Bar-Shalev Amos | director | 0 0% | $0 | 1 | 1 | <0.0001% |
| Camber Capital Management LLC | 10 percent owner | 10775000 13.3732% | $25M | 1 | 1 | <0.0001% |
| Bronfeld Zeev | 10066319 12.4936% | $23.35M | 0 | 1 | ||
| Bio-Cell Ltd | 10 percent owner | 10066319 12.4936% | $23.35M | 0 | 1 | |
| FROST PHILLIP MD ET AL | 10 percent owner | 7610167 9.4452% | $17.66M | 2 | 25 | +14.01% |
| Akirov Alfred | director | 4915383 6.1006% | $11.4M | 0 | 7 | |
| Dexcel Pharma Technologies Ltd. | 10 percent owner | 3637314 4.5144% | $8.44M | 0 | 2 | |
| Hurvitz Eli | director | 1514480 1.8797% | $3.51M | 0 | 1 | |
| Shaaltiel Yoseph | Executive VP, R&D | 463754 0.5756% | $1.08M | 4 | 16 | <0.0001% |
| Manor Moshe | President & CEO | 50000 0.0621% | $116,000.00 | 1 | 0 | <0.0001% |
| Maimon Yossi | Vice President & CFO | 10000 0.0124% | $23,200.00 | 1 | 13 | <0.0001% |
| Aviezer David | President & CEO | 0 0% | $0 | 0 | 11 | |
| Almon Einat Brill | SVP, Product Development | 0 0% | $0 | 0 | 12 |
$16,259,194 | 41 | 120.51% | $181.06M | |
$140,595,157 | 34 | 17.93% | $183.93M | |
$18,752,549 | 33 | -28.39% | $201.84M | |
$6,915,275 | 21 | -32.61% | $209.93M | |
$38,821,584 | 20 | -2.17% | $219.9M | |
$15,094,184 | 18 | -30.69% | $186.62M | |
$245,302 | 15 | -4.08% | $223.27M | |
$178,593,887 | 15 | -14.86% | $175.3M | |
Protalix BioTherapeutics, Inc. (PLX) | $4,701,608 | 14 | -4.34% | $186.93M |
$13,919,584 | 9 | -30.43% | $180.37M | |
$6,210,140 | 9 | -3.71% | $186.66M | |
$344,394 | 8 | -22.26% | $212.6M | |
$49,165,200 | 7 | 12.92% | $179.18M | |
$99,355,998 | 7 | -65.74% | $170.82M | |
$8,286,963 | 6 | 3.09% | $194.06M | |
$32,007,657 | 4 | -45.65% | $225.08M | |
$193,101 | 3 | -25.20% | $210.18M | |
$12,750 | 2 | -39.73% | $162.97M | |
$63,731 | 1 | -19.50% | $207.15M |
| Increased Positions | 42 | +56.76% | 2M | +12.84% |
| Decreased Positions | 27 | -36.49% | 688,846 | -4.96% |
| New Positions | 12 | New | 731,010 | New |
| Sold Out Positions | 5 | Sold Out | 60,973 | Sold Out |
| Total Postitions | 89 | +20.27% | 15M | +7.88% |
| Blackrock, Inc. | $6,179.00 | 4.44% | 3.55M | +181,358 | +5.38% | 2025-09-30 |
| Opaleye Management Inc. | $4,490.00 | 3.23% | 2.58M | +3M | New | 2025-09-30 |
| Renaissance Technologies Llc | $2,289.00 | 1.64% | 1.32M | -299,603 | -18.55% | 2025-09-30 |
| Northern Trust Corp | $1,570.00 | 1.13% | 902,459 | -177,264 | -16.42% | 2025-09-30 |
| Geode Capital Management, Llc | $1,426.00 | 1.03% | 819,777 | -6,556 | -0.79% | 2025-09-30 |
| Stratos Wealth Partners, Ltd. | $870.00 | 0.63% | 500,000 | +150,000 | +42.86% | 2025-09-30 |
| State Street Corp | $867.00 | 0.62% | 498,547 | +54,308 | +12.22% | 2025-09-30 |
| Vanguard Group Inc | $808.00 | 0.58% | 464,421 | -20,377 | -4.2% | 2025-09-30 |
| Connor, Clark & Lunn Investment Management Ltd. | $697.00 | 0.5% | 400,398 | -95,818 | -19.31% | 2025-09-30 |
| Ubs Group Ag | $331.00 | 0.24% | 190,276 | +115,126 | +153.19% | 2025-09-30 |